Abstract
Objective
Idiopathic inflammatory myopathies (IIM) are chronic, multisystemic, autoimmune diseases affecting mainly the skin and proximal muscles. In this study, we aimed to determine the factors that may predict the disease course and to investigate the effect of major complications on the disease course in juvenile IIM patients.
Methods
This retrospective, observational study was conducted in Ankara Pediatrics Hematology Oncology Training and Research Hospital between 2009 and 2019 and University of Health Sciences Turkiye, Ankara Bilkent City Hospital between 2019 and 2022 with patients who were followed up for at least 6 months with a diagnosis of IIM. Demographic, clinical, laboratory findings, myositis-specific antibodies, treatments, disease course and complications were recorded.
Results
Thirty patients with IIM were included in the study. Eighteen (60%) of the patients were female. The median age at diagnosis was 118.5 [inter quartile range (IQR): 76.5-139.5] months. Twenty-six (86.7%) patients had muscle weakness, 27 (90.0%) had skin manifestations, 11 (36.7%) had arthritis, 4 (13.3%) had gastrointestinal system involvement, 2 (6.6%) had generalized edema, 1 (3.3%) had pulmonary involvement, and 1 (3.3%) had cardiac involvement. The median follow-up period was 25 (IQR: 17.7-72.5) months. Monocyclic course was observed in 15 (50.0%), polycyclic in 4 (13.3%) and persistent in 11 (36.6%) patients. Calcinosis developed in 4 (13.3%) patients and severe steroid side effects in 3 (10%) patients. The 6th month Childhood Myositis Assessment Scale (CMAS) score was significantly correlated with monocyclic disease course.
Conclusion
CMAS score is useful tool in predicting the disease course in patients with IIM. Patients with low 6th month CMAS score should be carefully followed up considering the increased possibility of polycyclic/persistent course.
Keywords: Idiopathic inflammatory myopathy, juvenile dermatomyositis, prognosis, complications
References
Taborda AL, Azevedo P, Isenberg DA. Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. Clin Exp Rheumatol. 2014;32:188-93.
Papadopoulou C, Chew C, Wilkinson MGL, et al. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023;19:343-62.
Gonçalves Júnior J, Shinjo SK. Calcinosis in Juvenile Dermatomyositis-Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review. Curr Rheumatol Rep. 2024;26:53-68.
Lee CW, Muo CH, Liang JA, et al. Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score. Endocrine. 2016;52:86-92
Rhim JW. Juvenile dermatomyositis. J Rheum Dis. 2022;29:14-21.
Petty RE, Laxer R, Lindsley C, Wedderburn L, Fuhlbrigge RC, Mellins ED. Textbook of pediatric rheumatology. In: Clarissa A. Pilkington, Brian Michael Feldman, and Watchareewan Sontichai (ed) Juvenile Dermatomyositis and Other Inflammatory Muscle Diseases, 8th edn. Elsevier, OHCE, 2020; 360-75.
Singh S, Suri D, Aulakh R, et al. Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India. Clin Rheumatol. 2014;33:1675-9.
Lundberg IE. Expert perspective: management of refractory inflammatory myopathy. Arthritis Rheumatol. 2021;73:1394-407.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344-7.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975 ve 292:403-7.
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955-64.
Constantin T, Ponyi A, Orbán I, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary--clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity. 2006;39:223-32.
Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum. 1999;42:2213-9.
Lazarevic D, Pistorio A, Palmisani E, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013; 686-93.
Barut K, Aydin PO, Adrovic A, et al. Juvenile dermatomyositis: a tertiary center experience. Clin Rheumatol. 2017;36:361-6.
Gowdie PJ, Allen RC, Kornberg AJ, Akikusa JD. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis. 2013;16:561-7.
Hajialilo M, Ghorbanihaghjo A, Khabbazi A, et al. Long-term follow-up of 76 Iranian patients with idiopathic inflammatory myopathies. Int J Rheum Dis. 2018;21:1627-33.
Rajarathinam I, Raghuram J, Rao AP. Clinical Characteristics and Course of Patients with Juvenile Dermatomyositis - Case Series. Neurol India. 2022;70:300-3.
Challa D, Crowson CS, Niewold TB, Reed AM; CARRA Legacy Registry Investigators. Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry. Clin Rheumatol. 2018;37:1011-5.
Stringer E, Singh-Grewal D, Feldman BM. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Arthritis Rheum. 2008;58:3585-92.
Sanner H, Sjaastad I, Flatø B. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Rheumatology (Oxford). 2014;53:1578-85.
Barth Z, Schwartz T, Flatø B, et al. Association Between Nailfold Capillary Density and Pulmonary and Cardiac Involvement in Medium to Longstanding Juvenile Dermatomyositis. Arthritis Care Res (Hoboken). 2019;71:492-7.
Kishi T, Warren-Hicks W, Bayat N, et al. Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. Rheumatology (Oxford). 2021;60:2134-45.
Sener S, Basaran O, Batu ED, et al. Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature. Semin Arthritis Rheum. 2023;58:152133.
Gezgin Yıldırım D, Baglan E, Güngörer V, et al. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis. Int J Rheum Dis. 2023;26:1504-11.
Pagnini I, Vitale A, Selmi C, et al. Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms. Clin Rev Allergy Immunol. 2017;52:34-44.
Stenzel W, Goebel HH, Bader-Meunier B, Gitiaux C. Inflammatory myopathies in childhood. Neuromuscul Disord. 2021;31:1051-61.
Yeşilbaş O, Yıldız M, Yozgat CY, et al. A fatal interstitial lung disease in an anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody negative patient with juvenile dermatomyositis. Turk J Pediatr. 2021;63:903-8.
Binns EL, Moraitis E, Maillard S, et al. Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature. Pediatr Rheumatol Online J. 2017;15:77.
Jayakumar D, Zhang R, Wasserman A, Ash J. Cardiac Manifestations in Idiopathic Inflammatory Myopathies: An Overview. Cardiol Rev. 2019;27:131-7.
Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000;43:2368-77.
Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford). 2014;53:2204-8.
Yamasaki Y, Kobayashi N, Akioka S, et al. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study. Rheumatology (Oxford). 2021;60:4821-31.
McCann LJ, Livermore P, Wilkinson MGL, Wedderburn LR. Juvenile dermatomyositis. Where are we now? Clin Exp Rheumatol. 2022;40:394-403.
Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62:1446-511.
Varnier GC, Consolaro A, Cheng IL, et al. Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2023;62:163-9.
Wu JQ, Lu MP, Reed AM. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr. 2020;16:31-43.
